AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Screening in Primary Care of Advanced Liver Fibrosis in NAFLD and/or Alcoholic Patients

RecruitingNAAges 40 Years - 80 YearsAllUniversity Hospital, Angers
💬

In plain words

What the trial is, and whether it could suit you

The primary objective of the SOPRANO study is to compare two blood fibrosis tests, the eLIFT and the FibroMeter, for the screening of advanced liver fibrosis in patients with NAFLD and/or ALD from primary care centers.

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * NAFLD and/or ALD patient defined by at least 1 of the following criteria: * Excessive alcohol consumption: higher than 210 g / week (men), or 140 g / week (women) * Type 2 diabetes * at least 2 metabolic factors among BMI higher than or equal to 25 kg / m 2; Elevated blood pressure (antihypertensive drug, or systolic blood pressure higher than or equal to 130mmHg, or diastolic blood pressure higher than or equal to 85mmHg), Dyslipidemia (lipid-lowering drug, or HDL cholesterol lower to 40mg/dl (men) / 50mg/dl (women), or triglycerides higher than or equal to150mg/dl); Hyperferritinemia (higher than upper limit of normal from the laboratory) * Bright liver at ultrasonography without steatosis-inducing drug(systemic corticosteroids, tamoxifen, amiodarone, methotrexate) Following a protocol amendment, the 3 last investigating primary care centres will include NAFLD and/or ALD patients according to these updated criteria: * Excessive alcohol consumption: \>210 g/week in men or \>140 g/week in women, * AND/OR type 2 diabetes treated with insulin and/or at least two other anti-diabetic treatments, * AND with the following stratification: 30% with excessive alcohol consumption 65% with type 2 diabetes treated with insulin and/or at least two other anti-diabetic treatments 5% with both conditions (excessive alcohol consumption, AND type 2 diabetes treated with insulin and/or at least two other anti-diabetic treatments) * Patient's agreement to have a blood sample collected in a local laboratory participating in the study * Subjects covered by or having the rights to medical care assurance * Written informed consent obtained from subject Exclusion Criteria: * Already ongoing specialized follow-up for a chronic liver disease * Altered health status with poor short-term prognosis, not compatible with a screening procedure * Decompensated cirrhosis (hepatic encephalopathy, jaundice, ascites, variceal bleeding, hepatorenal syndrome) * Acute infection * Pregnancy, breastfeeding * Persons in detention by judicial or administrative decision * Person admitted to a health or social establishment for purposes other than research * Person subject to a legal protection measure * Person unable to express consent
💊

What it tests

  • eLIFT
📍

Where

13 sites
ANGERS
Angers, France
CHU Angers
Angers, France
BAUGE
Baugé-en-Anjou, France
BECON
Bécon-les-Granits, France
Chalonnes
Chalonnes-sur-Loire, France
COMBOURG
Combourg, France
LIFFRE
Liffré, France
Montreuil
Montreuil-Bellay, France

…and 5 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy